Be0101 50mg

After the tumors had grown to approximately 100 mm³, the tumor-bearing mice were divided randomly into different groups (n=5 per group). To test the synergistic effect of SGN1 and anti-PD-L1 therapy in vivo, mice were administered 2×10⁴ CFU/mouse SGN1 intravenously or PD-L1 mAb (150 µg/mouse, Bio X Cell, BE0101-50MG) intraperitoneally as monotherapies (n=5 per group). The mice in the SGN1-PD-L1 mAb group received a single intravenous injection of SGN1 (2×10⁴ CFU/mouse SGN1 on day 0) that combined intraperitoneal injection of PD-L1 mAb (150 µg/mouse, on day 1, 4, 7 of a 9-day cycle). The specific schematic view of the treatment plans was described in the figure 4A. In each group of mice, all mice were used to observe the tumor phenotype changes. The mice were euthanized at the end of the treatment, and their tumors were harvested and weighted using double-blinded evaluation. Single cell suspension of implanted tumors was prepared for flow cytometry analysis. Meanwhile, partial tumor samples were also for further western blot and histology.